CTOTClinical•globenewswire•
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease
Sentiment:Positive (70)
Summary
- Cognition and FDA align on enriched population, study design, and endpoints -
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 12, 2025 by globenewswire